PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10381483" target="_blank" >RIV/00216208:11110/18:10381483 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/18:10381483 RIV/00669806:_____/18:10381483 RIV/00064165:_____/18:10381483

Výsledek na webu

<a href="http://iv.iiarjournals.org/content/32/6/1551.long" target="_blank" >http://iv.iiarjournals.org/content/32/6/1551.long</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21873/invivo.11413" target="_blank" >10.21873/invivo.11413</a>

Jazyk výsledku

angličtina

Název v původním jazyce

PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study

Popis výsledku v původním jazyce

Aim: The aim of this study was to evaluate the clinical contribution of protein induced by vitamin K absence (PIVKA-II) for hepatocellular carcinoma (HCC) diagnostics and compare it with alpha-foetoprotein (AFP), a routinely used tumour marker. Materials and Methods: A total of 332 participants were enrolled in this study: 64 with HCC, 48 with liver metastases of colorectal cancer origin, 42 with liver cirrhosis and 178 healthy individuals. Serum levels of PIVKA-II were measured using the chemiluminescent assay of the Architect 1000i System (Abbott, USA) and AFP levels using the chemiluminescent assay by DxI 800 (Beckman Coulter, USA). Results: PIVKA-II achieved better clinical sensitivity than AFP and the difference in this sensitivity was statistically significant. PIVKA-II achieved the best sensitivity (96.9%) in distinguishing between the HCC and control groups with the proposed cut-off value of 60 mAU/ml. Conclusion: Our recommendation is for addition of PIVKA-II to the routine panel of HCC tumour markers.

Název v anglickém jazyce

PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study

Popis výsledku anglicky

Aim: The aim of this study was to evaluate the clinical contribution of protein induced by vitamin K absence (PIVKA-II) for hepatocellular carcinoma (HCC) diagnostics and compare it with alpha-foetoprotein (AFP), a routinely used tumour marker. Materials and Methods: A total of 332 participants were enrolled in this study: 64 with HCC, 48 with liver metastases of colorectal cancer origin, 42 with liver cirrhosis and 178 healthy individuals. Serum levels of PIVKA-II were measured using the chemiluminescent assay of the Architect 1000i System (Abbott, USA) and AFP levels using the chemiluminescent assay by DxI 800 (Beckman Coulter, USA). Results: PIVKA-II achieved better clinical sensitivity than AFP and the difference in this sensitivity was statistically significant. PIVKA-II achieved the best sensitivity (96.9%) in distinguishing between the HCC and control groups with the proposed cut-off value of 60 mAU/ml. Conclusion: Our recommendation is for addition of PIVKA-II to the routine panel of HCC tumour markers.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

In Vivo

ISSN

0258-851X

e-ISSN

—

Svazek periodika

32

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

4

Strana od-do

1551-1554

Kód UT WoS článku

000447885500035

EID výsledku v databázi Scopus

2-s2.0-85055180893